Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBC3DG)

• Drug Name: A-80426 Drug Info
• Synonyms: A-80426; CHEMBL268258; SCHEMBL647243; ZINC3810797; BDBM50057128; AKOS030558130; NCGC00378605-01
• Cross-matching ID:
  PubChem CID: 9928332
  TTD Drug ID: DMBC3DG

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[4]
Dihydroergocristine	DM5SQ1G	Alcohol dependence	6C40.2	Approved	[5]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[6]
Amosulalol	DML8QSZ	Hypertension	BA00-BA04	Approved	[7]
Amezinium	DM6I2WQ	Hypotension	BA20-BA21	Approved	[8]
Propylhexedrine	DMTBW2O	Obesity	5B81	Approved	[9]
Tetrahydrozoline	DMT57WC	Ocular disease	1F00.1Z	Approved	[10]
Rilmenidine	DM13PQW	Hypertension	BA00-BA04	Approved	[11]
Xylometazoline	DMKV32D	Allergic rhinitis	CA08.0	Phase 4	[12]
TNX-102	DMO1234	Fibromyalgia	MG30.01	Phase 3	[13]

Drug(s) Targeting Adrenergic receptor alpha-2A (ADRA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[14]
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[4]
Connexyn	DMF29Q5	Attention deficit hyperactivity disorder	6A05.Z	Approved	[15]
Guanfacine	DMPN5IH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[16]
A295	DM55GO2	Aggressive cancer	2A00-2F9Z	IND submitted	[17]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[18]
DSP-1200	DM4WSHG	Depression	6A70-6A7Z	Phase 1	[19]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[20]
NMI-870	DMU596F	Sexual dysfunction	HA00-HA01	Discontinued in Phase 2	[21]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[22]

Drug(s) Targeting Dopamine D4 receptor (D4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[23]
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[24]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[25]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[19]
L-745,870	DMTGR25	Psychotic disorder	6A20-6A25	Phase 2	[26]
NGD 94-1	DMM1Y8F	Schizophrenia	6A20	Phase 1	[27]
ABT-724	DMDQVY4	Erectile dysfunction	HA01.1	Discontinued in Phase 2	[28]
Lu-35138	DMQ7A35	Psychotic disorder	6A20-6A25	Discontinued in Phase 2	[29]
NGD-94-4	DMZ9WLO	Schizophrenia	6A20	Discontinued in Phase 1	[30]
PD-165167	DMD0GB4	Schizophrenia	6A20	Preclinical	[27]

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[31]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[32]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[23]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[33]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[34]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[35]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[36]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[23]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[23]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[23]

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[37]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[38]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[39]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[33]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[40]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[41]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[42]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[43]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[44]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[45]

Drug(s) Targeting Adrenergic receptor alpha-2B (ADRA2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[4]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[18]
AGN-199981	DMP5Y1A	Neuropathic pain	8E43.0	Phase 2	[46]
INDORAMIN	DMNSJFD	Hypertension	BA00-BA04	Withdrawn from market	[47]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[20]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[22]
WB-4101	DMQU8B1	N. A.	N. A.	Terminated	[48]
SK&F-104078	DMRADBU	N. A.	N. A.	Terminated	[47]
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[49]
R-226161	DM4BP7S	Discovery agent	N.A.	Investigative	[50]

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[51]
Haloperidol	DM96SE0	Delirium		Approved	[52]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[53]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[54]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[55]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[56]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[57]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[58]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[59]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[39]

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[23]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[60]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[61]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[62]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[33]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[63]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[64]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[65]
Treximet	DMU54QB	Migraine	8A80	Approved	[66]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[25]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Inhibitor	[1]
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Inhibitor	[1]
Adrenergic receptor alpha-2A (ADRA2A)	TTWG9A4	ADA2A_HUMAN	Inhibitor	[2]
Adrenergic receptor alpha-2B (ADRA2B)	TTWM4TY	ADA2B_HUMAN	Inhibitor	[2]
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Inhibitor	[2]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Inhibitor	[1]
Dopamine D4 receptor (D4R)	TTE0A2F	DRD4_HUMAN	Inhibitor	[2]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[3]

References

• [1] Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
• [2] Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
• [3] Structure-activity studies for a novel series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamine s possessing dual 5-HT upt... J Med Chem. 1997 Mar 28;40(7):1049-62.
• [4] Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
• [5] Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
• [7] Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
• [8] Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
• [9] Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
• [10] Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
• [11] Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
• [12] Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
• [13] Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
• [14] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [15] alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
• [16] Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
• [17] Clinical pipeline report, company report or official report of Klus Pharma
• [18] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [19] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [20] A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
• [21] Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
• [22] Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [24] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [26] Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
• [27] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [28] Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
• [29] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
• [30] I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.
• [31] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [32] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [33] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [34] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [35] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [36] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [37] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [38] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [39] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [40] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [41] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [42] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [43] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [44] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [45] Clinical pipeline report, company report or official report of Lundbeck.
• [46] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [47] Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
• [48] alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
• [49] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
• [50] Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
• [51] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [52] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [53] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [54] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [55] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [56] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [57] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [58] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [59] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [60] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [61] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [62] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [63] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [64] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [65] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [66] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).